Understand the source comparison
Ipamorelin News 2026: Peptide Comparison Table
The regulatory changes affecting ipamorelin have prompted many researchers to evaluate alternative growth hormone secretagogues. The table below compares ipamorelin to other commonly researched peptides in terms of mechanism, selectivity, regulatory status, an
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The regulatory changes affecting ipamorelin have prompted many researchers to evaluate alternative growth hormone secretagogues. The table below compares ipamorelin to other commonly researched peptides in terms of mechanism, selectivity, regulatory status, and procurement availability as of 2026.
- | Peptide | Mechanism of Action | Receptor Selectivity | Regulatory Status (2026) | Typical Research Dose (Rodent) | Procurement Availability | Professional Assessment ||—|—|—|—|—|—|| Ipamorelin | GHS-R1a agonist (ghrelin receptor) | High. Minimal cortisol/prolactin cross-reactivity | Removed from FDA bulk substances list; restricted compounding | 50–100 mcg/kg SC once or twice daily | Moderately restricted. Requires verified supplier and CoA | Best selectivity profile but hardest to source domestically; worth the procurement effort for studies requiring clean GH stimulation || GHRP-2 | GHS-R1a agonist | Moderate. Some cortisol/prolactin elevation | Similar restrictions as ipamorelin | 100–200 mcg/kg SC | Moderately restricted | Easier to source than ipamorelin but less selective; acceptable substitute if cortisol elevation is not a confounder || GHRP-6 | GHS-R1a agonist | Low. Significant appetite stimulation and cortisol response | Similar restrictions as ipamorelin | 100–200 mcg/kg